BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

963 related articles for article (PubMed ID: 14983501)

  • 21. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
    Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
    J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
    Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
    J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
    Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
    Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
    Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
    Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
    Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
    Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
    Meyer JS; Gersell DJ; Yim S
    Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
    Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
    Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and prognosis of mucinous tumors of the ovary.
    Kikkawa F; Nawa A; Kajiyama H; Shibata K; Ino K; Nomura S
    Gynecol Oncol; 2006 Oct; 103(1):171-5. PubMed ID: 16546243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histologic subtypes and laterality of primary epithelial ovarian tumors.
    Boger-Megiddo I; Weiss NS
    Gynecol Oncol; 2005 Apr; 97(1):80-3. PubMed ID: 15790441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial ovarian tumors of low malignant potential.
    Massad LS; Hunter VJ; Szpak CA; Clarke-Pearson DL; Creasman WT
    Obstet Gynecol; 1991 Dec; 78(6):1027-32. PubMed ID: 1945202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Borderline epithelial tumors of the ovary.
    Hart WR
    Mod Pathol; 2005 Feb; 18 Suppl 2():S33-50. PubMed ID: 15761465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma?
    Fukumoto M; Nakayama K
    Pathol Int; 2006 May; 56(5):233-9. PubMed ID: 16669871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
    Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
    Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome.
    Gotlieb WH; Flikker S; Davidson B; Korach Y; Kopolovic J; Ben-Baruch G
    Cancer; 1998 Jan; 82(1):141-6. PubMed ID: 9428490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms.
    Sainz de la Cuesta R; Goff BA; Fuller AF; Nikrui N; Eichhorn JH; Rice LW
    Obstet Gynecol; 1994 Jul; 84(1):1-7. PubMed ID: 8008300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules.
    Provenza C; Young RH; Prat J
    Am J Surg Pathol; 2008 Mar; 32(3):383-9. PubMed ID: 18300813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.